Patents by Inventor Jerome J. Schentag

Jerome J. Schentag has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10588857
    Abstract: The invention provides oral vaccine formulations which deliver an antigen in the vicinity of the distal ileum and the area of the ileal Brake and/or the appendix. These vaccines are useful in the treatment and/or prevention of variety of disorders, including viral and bacterial infections and cancers. Related methods of treatment which use the oral vaccine formulations of the invention are also provided.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 17, 2020
    Assignee: Therabiome, LLC
    Inventors: Jerome J. Schentag, Mohan Kabadi
  • Publication number: 20200069161
    Abstract: The present invention may be embodied as a retrievable device capable of sensing one or more properties of an individual (e.g., chemical or physical parameters). In use, the retrievable device can continuously determine the chemical concentrations within the vaginal tract. An embodiment of the retrievable device comprises a first housing having a light source and an image capture device, a second housing removably connected to the first housing and having a sensor, and a fitting for retrieving the device. The sensor may be an analyte sensor configured to obtain at least one measurement of a concentration of an analyte in a fluid. The analyte sensor comprises a sensor substance in a sol-gel material so the sensor substance reversibly interacts with an analyte of interest. In addition, the retrievable device can be configured to determine different physical parameters and re-implanted.
    Type: Application
    Filed: July 15, 2019
    Publication date: March 5, 2020
    Applicant: TheraSyn Sensors, Inc.
    Inventors: Jerome J. Schentag, Frank V. Bright, David T. D'Andrea
  • Publication number: 20200069598
    Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
    Type: Application
    Filed: July 31, 2019
    Publication date: March 5, 2020
    Inventors: JEROME J. SCHENTAG, Mary P. McCourt, Lawrence Mielnicki, Julie Hughes
  • Patent number: 10369114
    Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: August 6, 2019
    Assignee: THERASYN SENSORS, INC.
    Inventors: Jerome J. Schentag, Mary P. McCourt, Lawrence Mielnicki, Julie Hughes
  • Patent number: 10369111
    Abstract: The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not 5 limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically 10 diabetes, insulin resistance, obesity, hyperlipidemia and hypertension. The present invention restores altered probiotic organism imbalances that are characteristic of said diseases among others as well as defines a platform technology development for site specific delivery of probiotic organisms in the GI tract of a 15 mammal, most specifically the ileum and/or right colon of a human subject.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: August 6, 2019
    Assignee: Therabiome, LLC
    Inventors: Mohan Kabadi, Jerome J. Schentag
  • Patent number: 10349820
    Abstract: The present invention may be embodied as a retrievable device capable of sensing one or more properties of an individual (e.g., chemical or physical parameters, etc.) In use, the retrievable device can continuously determine the chemical concentrations within the vaginal tract. An embodiment of the retrievable device comprises a first housing having a light source and an image capture device, a second housing removably connected to the first housing and having a sensor, and a fitting for retrieving the device. The sensor may be an analyte sensor configured to obtain at least one measurement of a concentration of an analyte in a fluid. The analyte sensor comprises a sensor substance in a sol-gel material so the sensor substance reversibly interacts with an analyte of interest. In addition, the retrievable device can be configured to determine different physical parameters and re-implanted.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: July 16, 2019
    Assignee: TheraSyn Sensors, Inc.
    Inventors: Jerome J. Schentag, Frank V. Bright, David T. D'Andrea
  • Publication number: 20190175515
    Abstract: The present invention is directed to one or more macromolecules in a lipid vesicle oral formulation which targets intracellular receptors, in particular for peptides, proteins, nucleic acids and mixtures thereof, optionally in combination with small molecules. The invention encapsulates said macromolecules in a neutral lipid vesicle comprised of one or more cholesteryl esters. Unique properties of macromolecules encapsulated in said vesicles include high oral bioavailability, defined herein as in at least 50%, i.e., often in excess of 50% on the basis of oral to parenteral AUC. Non-limiting examples are provided, for large hydrophilic molecules such as peptides, proteins and nucleic acids which heretofore have been very poorly absorbed by the mammalian intestine. In prior art; said molecules are generally less than 25% bioavailable, even with protective coatings and optionally absorption enhancing component substances in the formulation.
    Type: Application
    Filed: August 23, 2017
    Publication date: June 13, 2019
    Inventors: Jerome J. Schentag, Mary P. McCourt, Lawrence Mielnicki
  • Publication number: 20180221286
    Abstract: The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension. The present invention restores altered probiotic organism imbalances that are characteristic of said diseases among others as well as defines a platform technology development for site specific delivery of probiotic organisms in the GI tract of a mammal, most specifically the ileum and/or right colon of a human subject.
    Type: Application
    Filed: January 18, 2018
    Publication date: August 9, 2018
    Inventors: Mohan Kabadi, Jerome J. Schentag
  • Patent number: 9907755
    Abstract: The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 6, 2018
    Assignee: Therabiome, LLC
    Inventors: Mohan Kabadi, Jerome J. Schentag
  • Publication number: 20180055780
    Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
    Type: Application
    Filed: May 24, 2017
    Publication date: March 1, 2018
    Inventors: Jerome J. Schentag, Mary P. Mccourt, Lawrence Mielnicki, Julie Hughes
  • Patent number: 9693968
    Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 4, 2017
    Inventors: Jerome J. Schentag, Mary P. McCourt, Lawrencee Mielnicki, Julie Hughes
  • Patent number: 9443060
    Abstract: Provided is a method for assessing cardiovascular risk in Metabolic Syndrome and Type 2 Diabetes patients. The method involves obtaining data from a Type 2 diabetes patient or a Metabolic Syndrome patient and determining a Fayad/Schentag index which includes a Glucose Supply Index (S) to an Insulin Demand Index (D) ratio. The Fayad/Schentag index is used in scoring cardiovascular risks of Metabolic Syndrome patients and for recommending and implementing therapeutic interventions that can be shown to lower cardiovascular risk.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: September 13, 2016
    Assignee: VOLANT HOLDINGS GMBH
    Inventors: Jerome J. Schentag, Joseph M. Fayad, Scott V. Monte
  • Publication number: 20160158320
    Abstract: Hydrogel lenses are infused with a drug for the treatment of posterior segment disease. The lenses are placed in contact with the subject's cornea. Drugs can be passively released from the hydrogel and can migrate around the globe of the eye to the posterior segment.
    Type: Application
    Filed: December 7, 2015
    Publication date: June 9, 2016
    Applicant: DIRECT CONTACT LLC
    Inventors: Clyde L. Schultz, Jerome J. Schentag
  • Publication number: 20160030361
    Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Jerome J. SCHENTAG, Mary P. McCOURT, Lawrence MIELNICKI, Julie HUGHES
  • Publication number: 20160022592
    Abstract: The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Inventors: Mohan KABADI, Jerome J. SCHENTAG
  • Publication number: 20150377860
    Abstract: The present invention can be described as an apparatus and cartridge for detecting the presence of an analyte in a fluid. The invention can also be described as a method of detecting the presence of an analyte in a fluid using the apparatus and cartridge. The method comprises the steps of clamping a sensor cartridge into a cartridge receiver of the apparatus, providing fluid to a fluid flow-path of the cartridge, illuminating at least a portion of a sensor, and using a photodetector to detect a change in the optical property of the sensor, wherein the change is caused by the presence or absence of an analyte in the fluid.
    Type: Application
    Filed: August 5, 2015
    Publication date: December 31, 2015
    Inventors: Jerome J. Schentag, David T. D'Andrea, Frank V. Bright
  • Patent number: 9216106
    Abstract: Hydrogel lenses are infused with a drug for the treatment of posterior segment disease. The lenses are placed in contact with the subject's cornea. Drugs can be passively released from the hydrogel and can migrate around the globe of the eye to the posterior segment.
    Type: Grant
    Filed: September 2, 2008
    Date of Patent: December 22, 2015
    Assignee: DIRECTCONTACT LLC
    Inventors: Clyde L. Schultz, Jerome J. Schentag
  • Publication number: 20150235002
    Abstract: Provided is a method for assessing cardiovascular risk in Metabolic Syndrome and Type 2 Diabetes patients. The method involves obtaining data from a Type 2 diabetes patient or a Metabolic Syndrome patient and determining a Fayad/Schentag index which includes a Glucose Supply Index (S) to an Insulin Demand Index (D) ratio.
    Type: Application
    Filed: April 2, 2015
    Publication date: August 20, 2015
    Inventors: Jerome J. Schentag, Joseph M. Fayad, Scott V. Monte
  • Patent number: 9103766
    Abstract: The present invention can be described as an apparatus and cartridge for detecting the presence of an analyte in a fluid. The invention can also be described as a method of detecting the presence of an analyte in a fluid using the apparatus and cartridge. The method comprises the steps of clamping a sensor cartridge into a cartridge receiver of the apparatus, providing fluid to a fluid flow-path of the cartridge, illuminating at least a portion of a sensor, and using a photodetector to detect a change in the optical property of the sensor, wherein the change is caused by the presence or absence of an analyte in the fluid.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: August 11, 2015
    Assignee: Breath Diagnostics, LLC
    Inventors: Jerome J. Schentag, David T. D'Andrea, Frank V. Bright
  • Patent number: 8999721
    Abstract: Provided is a method for assessing cardiovascular risk in Metabolic Syndrome and Type 2 Diabetes patients. The method involves obtaining data from a Type 2 diabetes patient or a Metabolic Syndrome patient and determining a Fayad/Schentag index which includes a Glucose Supply Index (S) to an Insulin Demand Index (D) ratio. The Fayad/Schentag index is used in scoring cardiovascular risks of Metabolic Syndrome patients and for recommending and implementing therapeutic interventions that can be shown to lower cardiovascular risk.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: April 7, 2015
    Assignee: Therabrake, Inc.
    Inventors: Jerome J. Schentag, Joseph M. Fayad, Scott V. Monte